Vitamin B-6 restriction tends to reduce the red blood cell glutathione synthesis rate without affecting red blood cell or plasma glutathione concentrations in healthy men and women¹⁻³

Yvonne Lamers, Bruce O’Rourke, Lesa R Gilbert, Christine Keeling, Dwight E Matthews, Peter W Stacpoole, and Jesse F Gregory III

ABSTRACT

Background: Glutathione plays various protective roles in the human body. Vitamin B-6 as pyridoxal-5′-phosphate (PLP) is required as the coenzyme in the formation of glutathione precursors. Despite this obligatory role of PLP, previous studies from this laboratory showed that vitamin B-6 deficiency caused elevated glutathione concentrations in rat liver and human plasma.

Objective: Our aim was to determine the effect of marginal vitamin B-6 deficiency (plasma PLP 20–30 nmol/L) on the rate of red blood cell (RBC) glutathione synthesis.

Design: We measured plasma and RBC glutathione concentrations and the fractional and absolute synthesis rates of RBC glutathione using the stable-isotope-labeled glutathione precursor [1,2-13C2]glycine in 13 healthy volunteers aged 21–39 y.

Results: Dietary vitamin B-6 restriction did not significantly affect the glutathione concentration in plasma (6.9 ± 1.9 compared with 6.7 ± 1.1 μmol/L) or RBCs (2068 ± 50 compared with 2117 ± 48 μmol/L). For RBC glutathione, the mean fractional synthesis rates were 54 ± 5%/d and 43 ± 4%/d (P = 0.10), and the absolute synthesis rates were 1116 ± 100 and 916 ± 92 μmol·L⁻¹·d⁻¹ (P = 0.14) before and after vitamin B-6 restriction, respectively.

Conclusions: Marginal vitamin B-6 deficiency tended to decrease mean RBC glutathione synthesis with no effect on RBC glutathione concentration, but the responses varied widely among individuals. Because the cysteine concentration in plasma and RBC did not change during vitamin B-6 restriction, we conclude that the effects of marginal vitamin B-6 deficiency on glutathione synthesis are not caused by altered precursor concentrations. Am J Clin Nutr 2009;90:336–43.

INTRODUCTION

Glutathione is a vital factor in metabolic protective functions, including the reduction of hydroperoxides, the quenching of free radicals, and the detoxification of xenobiotics (1, 2). Glutathione synthesis from glutamate, cysteine, and glycine is tightly regulated, with its determinants including the activity of γ-glutamylcysteine synthetase and the intracellular availability of cysteine (2, 3). Cysteine can be synthesized from methionine via the transulfuration pathway. Both enzymes of the transulfuration pathway—cystathionine β-synthase and cystathionine γ-lyase—require vitamin B-6 in the form of pyridoxal-5′-phosphate (PLP) as coenzyme. PLP also serves as a coenzyme in the formation of glycine from serine through serine hydroxymethyltransferase.

Marginal vitamin B-6 deficiency, defined as a plasma PLP concentration between 20 and 30 nmol/L (4), occurs frequently (5) and is associated with coronary artery disease (6–8), stroke (9), and an elevated risk of Alzheimer disease (10). The mechanisms responsible for linkages between vitamin B-6 status and chronic disease have not yet been established.

A previous study from this laboratory showed that hepatic glutathione was inversely related to the dietary pyridoxine concentration over a range from fully adequate (2 mg/kg diet) through moderate (0.5 mg/kg diet) and pronounced deficiency (0.1 mg/kg) in rats (11). Plasma glutathione increased significantly during dietary vitamin B-6 restriction in healthy young men and women (12). The mechanism by which reduced vitamin B-6 status affects mammalian glutathione metabolism remains unclear. One may speculate that increases in tissue or blood glutathione might be induced by an inflammatory state (13) and oxidative stress (14–16) related to vitamin B-6 deficiency. Oxidative conditions potentially promote transsulfuration flux by activating cystathionine β-synthase (17, 18) and glutathione synthesis via activation of γ-glutamylcysteine ligase and glutathione synthetase (18). On the basis of the observations of our previous protocols and the reported connection between vitamin B-6 deficiency and oxidative stress, we hypothesize that glutathione synthesis increases after vitamin B-6 restriction in humans despite the essential role of PLP in the production of glutathione precursors.

¹ From the Food Science and Human Nutrition Department, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL (YL and JFG); the Department of Chemistry, University of Vermont, Burlington, VT (BO and DEM); the Division of Endocrinology and Metabolism, Department of Medicine, University of Florida, Gainesville, FL (LRG, CK, and PWS); and the Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL (PWS).

² Supported by NIH grant DK072398 and General Clinical Research Center grant M01-RR0082.

³ Address correspondence to JF Gregory, Food Science and Human Nutrition Department, University of Florida, Gainesville, FL 32611-0370. E-mail: jfgy@ufl.edu.

Received March 9, 2009. Accepted for publication May 19, 2009.

First published online June 10, 2009; doi: 10.3945/ajcn.2009.27747.
Red blood cell (RBC) glutathione synthesis rates have been determined in humans with the use of stable-isotope-labeled glutathione precursors, such as glycine (19–23) or cysteine (24–27). RBCs are a major source of glutathione (28). As previously reported (29), we designed a steady state stable-isotope tracer infusion protocol to assess the effect of marginal vitamin B-6 deficiency on whole-body glycine kinetics in healthy men and women. This protocol used [1,2-13C2]glycine before and after dietary vitamin B-6 restriction. Our aim was to quantify the fractional synthesis rate (FSR) and the absolute synthesis rate (ASR) of RBC glutathione and to determine their dependence on vitamin B-6 status in vivo. We also report plasma and RBC concentrations of glutathione and related amino acids before and after vitamin B-6 restriction in this group of 13 healthy men and women.

SUBJECTS AND METHODS

Subjects

Volunteers underwent a physical examination and were screened by standard clinical measures of hematological, hepatic, renal, and thyroid function. Medical history, dietary habits, and demographic data were assessed by a questionnaire. Of 37 recruited healthy male and nonpregnant female volunteers, 23 met the following inclusion criteria: age between 20–40 y, no history of gastrointestinal surgery, abnormal kidney or thyroid function, or any other chronic disease; no smoking or chronic drug use or alcoholism; no vitamin, amino acid, or protein supplementation; no chronic consumption of a high-protein diet; and no history of gastrointestinal surgery, abnormal kidney or thyroid function, or any other chronic disease. Of these, 14 were men, 2 were premenopausal women, and 7 were postmenopausal women. All selected subjects met the following inclusion criteria: age between 20–40 y, no history of gastrointestinal surgery, abnormal kidney or thyroid function, or any other chronic disease; no smoking or chronic drug use or alcoholism; no vitamin, amino acid, or protein supplementation; no chronic consumption of a high-protein diet; and a body mass index (in kg/m2) <28. All selected subjects were in adequate nutritional status for serum folate (28.1 ± 4.6 pmol/L), plasma PLP (49.3 ± 12.7 pmol/L), and plasma total homocysteine (<12 μmol/L).

Before the study, 6 of the 23 subjects that passed screening withdrew because of personal reasons or scheduling problems. Three subjects were withdrawn during intervention because of changes in health status and one withdrew for personal reasons. All subjects gave written informed consent. The University of Florida Institutional Review Board and the General Clinical Research Center (GCRC) Scientific Advisory Committee reviewed and approved this protocol.

Dietary treatment

All meals were prepared by the Bionutrition Unit of the GCRC. The subjects consumed nutritionally adequate meals with a standardized composition for 2 d to minimize dietary variation immediately before the first infusion. Subjects began consuming a vitamin B-6–restricted diet (0.32–0.38 mg vitamin B-6/d) on the day after the first infusion and continued this regimen for 28 consecutive days (29–31). During this period, the subjects consumed breakfast at the GCRC, were given a take-out lunch and snack to eat at their convenience, and returned to the GCRC to consume their evening meal. We compensated for any vitamin and mineral inadequacies of the study diets (other than vitamin B-6) by administering custom supplements daily to the subjects. Compliance with the dietary regimen was monitored by weekly measurements of plasma PLP as described below. After the second infusion day, an over-the-counter multivitamin-multimineral supplement was provided to the subjects to facilitate restoration of normal vitamin B-6 status.

Isotope infusion protocol

The isotope infusion protocol was previously described in detail (29, 32). [1,2-13C2]Glycine, 1-[5,5,5-2H3]leucine and sodium [13C]bicarbonate were purchased from Cambridge Isotopes Laboratories (Andover, MA). The parenteral solutions of these compounds were prepared in isotonic saline, filter sterilized, and analyzed to ensure the lack of pyrogenicity and microbial contamination.

Subjects were admitted to the GCRC on the evening before the infusion protocol and consumed no food or drinks, except water, between 2100 and the first blood draw. On the morning of the infusion, a catheter was inserted in the antebrachial vein of each arm: one for the tracer infusion and one for blood collection. Fasting blood samples were collected 2 h before infusion (at ~0700) for the measurement of plasma PLP, serum folate, vitamin B-12, and plasma total homocysteine concentrations. Infusions were initiated at ~0900 with a 5-min, ~20 mL priming dose that delivered 9.26 μmol [1,2,13C2]glycine/kg, 1.87 μmol [5,5,5-2H3]leucine/kg, and 2.15 μmol NaH13CO3/kg. The 9-h constant infusion followed immediately thereafter at a rate of ~20 mL/h to provide 9.26 μmol [1,2,13C2]glycine/kg and 1.87 μmol [5,5,5-2H3]leucine/kg.

Blood samples were taken at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7.5, and 9 h of the infusion. The samples were placed immediately on ice and centrifuged within 15 min after the blood draw (1500 × g, 4°C, 10 min). Plasma was stored in microcentrifuge tubes at −80°C. After removal of the buffy coat, RBCs were washed twice with phosphate-buffered saline (pH 7.4), lysed in distilled water in a 1:1 dilution, frozen in liquid nitrogen, and stored at −80°C until analyzed.

The subjects received a nutritive formula hourly starting 2 h before the infusion to maintain a fed state (33). This formula provided a balanced pattern of amino acids at a rate based on requirements of 0.8 g protein · kg−1 · d−1, which equals an hourly protein dose of ~0.03 g/kg with 5.23 and 5.44 kJ · kg−1 · d−1 for women and men, respectively. The formula further provided an adequate energy intake according to the requirements of 126 and 130 kJ · kg−1 · d−1 for women and men, respectively.

Sample analyses

Screening measurements

Serum folate and vitamin B-12 were analyzed with the use of a chemiluminescence-based assay (Elecsys; Roche Diagnostics, Indianapolis, IN). Plasma total homocysteine concentrations were measured as the ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate derivative by reversed-phase HPLC with fluorescence detection (34).

Plasma and RBC concentrations of amino acids and PLP

Plasma and RBC glutathione, cysteine, and cysteinyl-glycine concentrations were measured as described for plasma total homocysteine screening by reversed-phase HPLC with fluorescence detection (34). Plasma and RBC PLP concentrations were measured as the semicarbazone derivative by reversed-phase
HPLC with fluorescence detection (35, 36). Hemoglobin from lysed RBCs was measured with the use of a commercial spectrophotometric procedure (HemoCue Hb 201®; HemoCue AB, Ängelholm, Sweden).

Gas chromatography–mass spectrometry determination of amino acid isotopic enrichment and concentration

RBC amino acids were isolated, derivatized, and analyzed by gas chromatography–mass spectrometry (GC-MS) in electron capture negative ionization mode as previously described (37). The relative abundance of specific ions was determined by selected-ion monitoring at the following m/z ratios: glycine (293–295) and leucine (349–352). Isotopic enrichments are expressed as molar ratios (mol% excess) of labeled to unlabeled isotopomers after correction for the natural abundance of stable isotopes, essentially as performed by Storch et al (33).

Liquid chromatography–mass spectrometry analysis of RBC glutathione isotopic enrichment

Whole-blood glutathione was isolated and derivatized from a modified method developed by Guan et al (38). Aliquots of whole blood (150 μL) were transferred to 1.5-mL conical microcentrifuge tubes, and the tubes were frozen at −80°C, thawed, and vortex mixed. This procedure was repeated 3 times to lyse the RBCs in the whole-blood aliquot. A 300-μL aliquot of 10 mmol/L Ellman’s solution (39.6 mg 5,5'-dithiobis(2-nitrobenzoic acid); Sigma-Aldrich, St Louis, MO) in 10 mL of 100 mmol ammonium bicarbonate buffer solution/L, adjusted to pH = 7.5) was added to each microcentrifuge vial; the vials were vortex mixed again, allowed to sit at room temperature for 15 min, and the supernatant fluid was transferred to a second microcentrifuge tubes, and the tubes were frozen at −80°C, thawed, and vortex mixed. This procedure was repeated 3 times to lyse the RBCs in the whole-blood aliquot. A 150-μL aliquot of 200 g sulfosalicylic acid solution/L was added, and each microcentrifuge vial was vortex mixed again. The vials were centrifuged (10,000 × g) for 15 min, and the supernatant fluid was transferred to a second microcentrifuge vial and centrifuged again (10,000 × g) for 15 min. The supernatant fluid of each vial was then carefully transferred to 250-μL polypropylene autosampler vials and stored at −80°C until analyzed.

The derivatized glutathione samples were measured for 13C tracer content by LC-MS by using a Thermo-Finnigan Surveyor LC coupled with a Thermo-Finnigan (San Jose, CA) LCQ Deca XP Plus ion trap mass spectrometer, configured in positive electrospray ionization (ESI) mode. The ESI spray voltage was set at 4.5 kV; sheath gas (N2) was kept at a setting of 40, and the capillary temperature was maintained at 225°C. The LC column used was an Atlantis dC18, 1 × 150-mm, 3-μm bead column (Waters Corp, Milford, MA) kept at 40°C. The LC was run isocratically at 87% water, 12.5% acetonitrile, and 0.5% glacial acetic acid. The total run time was 11 min, with a mobile phase flow of 55 μL/min and a typical retention time for derivatized glutathione of ~7 min. The LC effluent was diverted away from the ESI source for the initial 3 min of each LC run to keep any unreacted Ellman’s solution and residual sulfosalicylic acid from entering the ESI-LC-MS source. All mass spectrometry data were collected in “zoom scan” mode at ~1 scan/s covering the isotopic envelope for the [M+H]+ ion of the derivatized glutathione (m/z = 504.5–508.5) to maximize mass resolution between isotopomers. After data acquisition, the intensity of each mass was averaged for the glutathione peak by using the Thermo-Finnigan Xcalibur Qual browser software. The peak areas for the [M+H]+ ion for unlabeled glutathione (m/z = 505) and [13C2]glutathione (m/z = 507) were then exported to an Excel worksheet, and the area ratios were converted to enrichment as mole% excess 13C2-glutathione with the use of standard equations.

Kinetic principles and analysis

As reported previously (29, 32), the combined use of [1,2-13C2]glycine and [2H3]leucine permits determination of the kinetics of whole-body glycine turnover, the conversion of glycine to serine, the rate of glycine decarboxylation, and its role as a source of 1-carbon units in 1-carbon metabolism. [2H3]Leucine was included to evaluate any nutritional effects on protein turnover as indicated by leucine flux (31, 39). The plateau enrichment (Ep) for all infused amino acid tracers was calculated as the mean of the plasma isotopic enrichments for the ~1.5-h to 9-h time points for the infused [13C2]glycine and [2H3]leucine tracers. Steady state kinetics of amino acid tracers were calculated by using standard equations (40) as described earlier (29, 32). The flux of leucine (Q Leu) in the plasma pool was calculated as

\[
Q_{\text{Leu}} = I_{\text{Leu}} \times \left( \frac{E_{\text{g}}}{E_{\text{p}}(\text{Leu})} - 1 \right)
\]

where \(I_{\text{Leu}}\) is the [2H3]leucine infusion rate, \(E_{\text{g}}\) is the enrichment of the [2H3]leucine tracer, and \(E_{\text{p}}(\text{Leu})\) is the plateau enrichment of [2H3]leucine in plasma.

Glycine flux \(Q_{\text{Gly}}\) was calculated as

\[
Q_{\text{Gly}} = I_{\text{Gly}} \times \left( \frac{E_{\text{Gly}}}{E_{\text{p}}(\text{Gly})} - 1 \right)
\]

where \(I_{\text{Gly}}\) is the [13C2]glycine infusion rate, \(E_{\text{Gly}}\) is the enrichment of the [13C2]glycine tracer, and \(E_{\text{p}}(\text{Gly})\) is the plateau enrichment of plasma [13C2]glycine corrected for intracellular overestimation (41, 42).

The FSR represents the fraction of the total pool that is synthesized per unit of time. The direct incorporation of the infused [1,2-13C2]glycine tracer (glycine M+2) in glutathione synthesis was determined and, thus, the synthesis of glutathione M+2. The FSR of RBC glutathione was approximated by using the initial rate of glutathione M+2 enrichment (slope of linear increase among the time points 4, 6, 7.5, and 9 h after infusion) and the estimated plateau enrichment of RBC glycine (EpRBC glycine).

\[
\text{FSR glutathione} = \text{initial rate of RBC glutathione } M+2 \text{ enrichment}/\text{EpRBC glycine}
\]

The RBC glycine enrichment at plateau (EpRBC glycine) was determined by fitting enrichment data to single exponential curves defined by the equation

\[
E = E_i(1 - e^{-kt})
\]

where \(E\) is the enrichment at time \(t\) (h), \(E_i\) is the enrichment at infinity (ie, plateau enrichment), and \(k\) is the rate constant (h⁻¹) from the fitted curve (43). Data were fit to this single exponential
regression equation by using the “exponential rise to maximum” function of SigmaPlot 2002 (SPSS version 8.02; SPSS, Rochester, MN). The ASR was derived from the $F_{SR_{glutathione}}$ and the RBC total glutathione pool:

$$ASR_{glutathione} = F_{SR_{glutathione}} \times \text{total RBC glutathione concentration} \quad (5)$$

**Statistical analysis**

In all tracer measurements, isotopic enrichment was expressed as the ratio of labeled to nonlabeled isotopomers after correction for the natural abundance of stable isotopes. All data are presented as means ± SEMs. A paired $t$ test was used to assess differences between normal vitamin B-6 status and marginal vitamin B-6 deficiency. Correlations between static and dynamic parameters of glutathione synthesis were determined with the use of the Spearman’s rank correlation coefficient. Linear regression was used to determine the influence of static and dynamic variables on the rate of glutathione synthesis before and after vitamin B-6 restriction and on the change in the ASR and FSR of RBC glutathione. Tertiles of RBC glutathione FSR were evaluated by using one-factor ANOVA, with multiple comparisons performed by using the Holm-Sidak method. Data were analyzed by using Microsoft Office Excel 2007 (Microsoft Corporation, Redmond, WA), SigmaStat 3.0, and SPSS 16.0 (SPSS Inc, Rochester, MN).

**RESULTS**

Dietary vitamin B-6 restriction significantly reduced the plasma PLP concentration (Table 1) by 55 ± 3%. All 13 subjects had reached the range of plasma PLP associated with marginal vitamin B-6 deficiency after 22 ± 2 d of consuming the vitamin B-6–restricted diet. Concurrent with the decrease in plasma PLP concentration, vitamin B-6 restriction significantly reduced the RBC PLP concentration (Table 1) by 18 ± 2%. Marginal vitamin B-6 deficiency did not alter the plasma and RBC concentrations of glutathione, cysteine, and cysteinyl-glycine. As reported previously (29), these subjects showed no change in plasma serine, methionine, or total homocysteine concentrations, whereas their plasma glycine and cystathionine concentrations significantly increased because of vitamin B-6 restriction.

The progressive isotopic enrichment of RBC glutathione and its precursor RBC glycine in this protocol are presented in Figure 1. The means for FSR and ASR of RBC glutathione (Table 2) were slightly lower in marginal vitamin B-6 deficiency; however, this did not reach statistical significance ($P = 0.10$ and $P = 0.14$, respectively). The individual FSR of RBC glutathione responded to vitamin B-6 restriction, ranging from a 58% decrease to a 45% increase (Figure 2A). The individual ASRs of RBC glutathione ranged from a 57% decrease to a 58% increase (Figure 2B). To further examine the heterogeneity of the FSR response, we ranked FSR values according to the extent and direction of absolute change due to vitamin B-6 restriction and divided them into tertiles (Table 3). ASR and FSR of RBC glutathione at normal vitamin B-6 status significantly correlated with the extent of change in ASR and FSR observed due to vitamin B-6 restriction, respectively (ASR: $\rho = -0.698$, $P < 0.01$; FSR: $\rho = -0.692$, $P < 0.01$). The change in RBC PLP concentration in response to vitamin B-6 restriction was significantly related to the change in RBC cysteine concentration.

**TABLE 1**

Concentration of plasma and red blood cell (RBC) pyridoxal-5′-phosphate (PLP), glutathione, total cysteine, and cysteinylglycine before and after dietary vitamin B-6 restriction

<table>
<thead>
<tr>
<th></th>
<th>At normal vitamin B-6 status</th>
<th>At marginal vitamin B-6 deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma PLP (nmol/L)</td>
<td>55 ± 4</td>
<td>23 ± 1(^2)</td>
</tr>
<tr>
<td>RBC PLP (pmol/g hemoglobin)</td>
<td>429 ± 19</td>
<td>352 ± 14(^2)</td>
</tr>
<tr>
<td>Plasma glutathione (µmol/L)</td>
<td>6.9 ± 1.9</td>
<td>6.7 ± 1.1</td>
</tr>
<tr>
<td>RBC glutathione (µmol/L packed red cells)</td>
<td>2068 ± 50</td>
<td>2117 ± 48</td>
</tr>
<tr>
<td>Plasma total cysteine (µmol/L)</td>
<td>237 ± 33</td>
<td>237 ± 29</td>
</tr>
<tr>
<td>RBC total cysteine (nmol/g hemoglobin)</td>
<td>141 ± 8</td>
<td>144 ± 8</td>
</tr>
<tr>
<td>Plasma cysteinylglycine (µmol/L)</td>
<td>31.2 ± 1.4</td>
<td>29.7 ± 1.3</td>
</tr>
<tr>
<td>RBC cysteinylglycine (nmol/g hemoglobin)</td>
<td>193 ± 15</td>
<td>200 ± 18</td>
</tr>
</tbody>
</table>

\(^1\) All values are means ± SEMs; \(n = 13\).

\(^2\) Significantly different from normal vitamin B-6 status, \(P < 0.0001\) (paired t test).

**FIGURE 1.** Mean (±SEM) red blood cell (RBC) glutathione and glycine enrichments before (●) and after (○) vitamin B-6 restriction.
Linear regression showed that the change in ASR and FSR of RBC glutathione in response to vitamin B-6 restriction were both negatively dependent on the FSR at normal vitamin B-6 status (Figure 3).

**DISCUSSION**

Vitamin B-6 depletion and marginal vitamin B-6 deficiency have been shown to increase glutathione concentrations in rat liver (11, 44) and human plasma (12). To our knowledge, this was the first study to investigate the effect of vitamin B-6 status on in vivo glutathione synthesis in healthy men and women. We showed that marginal vitamin B-6 deficiency tended to decrease RBC glutathione synthesis rates without affecting the plasma and RBC total glutathione concentration. The response of RBC glutathione synthesis rate to vitamin B-6 restriction varied greatly among subjects and was shown to depend on the initial FSR value (Figure 3). Changes in RBC glutathione synthesis rates were not predicted by the concentration or extent of change in plasma and RBC cysteine and glutathione. Thus, the effect of marginal

![Figure 2](https://example.com/figure2.jpg)  
**FIGURE 2.** Individual fractional synthesis rate (FSR) and absolute synthesis rate (ASR) of red blood cell glutathione before and after vitamin B-6 restriction in 13 healthy men and women. Symbols represent individual subjects.

![Figure 3](https://example.com/figure3.jpg)  
**FIGURE 3.** Linear regression between the change in fractional synthesis rate (FSR) and absolute synthesis rate (ASR) of red blood cell glutathione after vitamin B-6 restriction and the initial FSR value at normal vitamin B-6 status in 13 healthy men and women.

### TABLE 2

<table>
<thead>
<tr>
<th></th>
<th>Normal vitamin B-6 status</th>
<th>Marginal vitamin B-6 deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSR of RBC glutathione (%/d)</td>
<td>53.7 ± 4.5</td>
<td>43.2 ± 4.1</td>
</tr>
<tr>
<td>ASR of RBC glutathione (μmol · L⁻¹ · d⁻¹)</td>
<td>1116 ± 100</td>
<td>916 ± 92</td>
</tr>
<tr>
<td>Whole-body glycine flux (μmol · kg⁻¹ · h⁻¹)</td>
<td>448 ± 20</td>
<td>446 ± 16</td>
</tr>
<tr>
<td>Whole-body leucine flux (μmol · kg⁻¹ · h⁻¹)</td>
<td>106 ± 4</td>
<td>106 ± 7</td>
</tr>
</tbody>
</table>

All values are means ± SEMs; n = 13.

### TABLE 3

<table>
<thead>
<tr>
<th></th>
<th>Absolute change in FSR of RBC glutathione (%/d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper tertile (n = 5)</td>
<td>11.5 ± 3.4a</td>
</tr>
<tr>
<td>Middle tertile (n = 4)</td>
<td>−12.6 ± 3.1b</td>
</tr>
<tr>
<td>Lower tertile (n = 4)</td>
<td>−35.8 ± 2.2c</td>
</tr>
</tbody>
</table>

All values are means ± SEMs. Means with different superscript letters are significantly different, P < 0.001 (one-factor ANOVA with multiple comparisons performed by using the Holm-Sidak method).
VITAMIN B-6 DEPENDENCE ON GLUTATHIONE SYNTHESIS

341

vitamin B-6 deficiency on RBC glutathione synthesis rates appeared to be unrelated to the supply of the precursor amino acid cysteine. This finding is consistent with recent results of mathematical modeling simulations that predicted the effect of mild vitamin B-6 deficiency on blood glutathione concentration to be solely related to increased oxidative stress and not to the reduced velocity of PLP-dependent enzymes involved in cysteine formation (45). The variability in responses among subjects might result from factors influencing the activity and expression of γ-glutamyl-cysteine-synthetase, eg antioxidants and hormones such as insulin and glucocorticoids (1). Because deficiencies of γ-glutamyl-cysteine-synthetase and glutathione synthetase occur very rarely and are related to severe clinical symptoms (46), we do not believe that the observed variation in the basal rate of glutathione synthesis was associated with genetic variation. Furthermore, we were unable to postulate a mechanism by which cellular PLP depletion would directly alter glutathione synthesis.

Despite the fact that marginal vitamin B-6 deficiency yielded substantial and individually varied glutathione synthesis responses, plasma and RBC glutathione concentrations remained constant in our subjects. Similar findings were reported by Lyons et al (26), who observed reduced whole-blood glutathione synthesis rates but unaltered whole-blood glutathione concentrations after a 10-d sulfur amino acid–free diet in healthy men. In addition, mathematical modeling predicted constant blood glutathione concentrations during increasing oxidative stress and decreasing cytoplasmic (largely hepatic) glutathione concentrations (45). A possible explanation for this observation is a reduced glutathione turnover (26), potentially caused by reduced glutathione transport (47). In rat heart and liver tissues, a more severe vitamin B-6 deficiency induced an increase in glutathione peroxidase activity and to a lesser extent in glutathione reductase activity (15). This shift in enzyme activity evoked a decrease in the ratio of reduced to oxidized glutathione, whereas glutathione concentrations remained unaltered (15). Although our results indicate that the effects of marginal vitamin B-6 deficiency on glutathione synthesis are independent of the cysteine supply, the underlying mechanisms responsible for the variation in response in glutathione synthesis with concurrently constant RBC glutathione concentration remain to be determined.

Cysteine formation through the transsulfuration pathway is an important source of cysteine for glutathione synthesis. The dependence of glutathione synthesis on cystathionine β-synthase was shown in an in vitro model in which the glutathione concentration decreased by half within 17.5 min after inactivation of cystathionine β-synthase (48). As shown in this study and previously (12), marginal vitamin B-6 deficiency did not alter plasma or RBC cysteine concentrations. Furthermore, the hepatic cysteine concentration was maintained in rats with moderate levels of deficiency (11). In vivo cysteine flux is maintained in human vitamin B-6 deficiency states (12). Likewise, this research group has shown that the in vitro activity of hepatic cystathionine γ-lyase is depressed even in rats with mild vitamin B-6 deficiency (11), but the hepatic cysteine concentration in rats is approximately constant over a wide range of moderate vitamin B-6 deficiency states (11). We previously proposed that elevated cystathionine, under conditions in which cystathionine is lower than the Michaelis constant for cystathionine γ-lyase, compensates at least partially for the reduction in cystathionine γ-lyase caused by PLP depletion (11, 12) to allow transsulfuration flux to be maintained in marginal vitamin B-6 deficiency. We suggest that cysteine formation through transsulfuration is resilient to marginal vitamin B-6 deficiency and, thus, cysteine production does not limit glutathione synthesis at this level of deficiency. This situation differs from more severe vitamin B-6 deficiency that is capable of reducing cysteine availability to the extent glutathione synthesis is impaired and glutathione concentration is reduced (49).

Cystathionine and cysteine contribute equally to glutathione synthesis as shown in rat hepatocytes (50). At an adequate intake of methionine, the dietary cysteine supply did not alter the RBC glutathione synthesis rate in healthy adults (51). A diet free of methionine and cysteine significantly reduced the whole-blood glutathione synthesis rate, whereas it did not affect the whole-blood glutathione concentration (26). In our study, the subjects consumed an adequate supply of protein (73 ± 4 g/d) and of methionine and cysteine (1.7 ± 0.1 and 1.3 ± 0.1 mg/d) during the 28-d vitamin B-6–restricted diet. Cysteine in plasma fluctuates depending on protein and glutathione breakdown in tissues (3). Glutathione breakdown has been shown to account for 50% of cysteine flux (24). A 30% decrease in the plasma cysteine concentration after a 1-d sulfur amino acid–free diet (26) could be explained primarily by reduced protein breakdown. In our study, marginal vitamin B-6 deficiency did not change whole-body protein turnover as indicated by constant whole-body leucine flux. The observed variation in effects of vitamin B-6 restriction on the glutathione synthesis rate was, therefore, unrelated to changes in protein turnover or sulfur amino acid intake.

RBC glutathione has widely been used in the quantification of in vivo glutathione synthesis rate (19–22). In rabbits (52) and pigs (53), faster glutathione synthesis was determined in liver than in blood cells. Compared with control rats without infection, septic rats had lower glutathione synthesis rates in whole blood but higher rates in liver, spleen, large intestine, lung, muscle, and heart (54). This observation would explain our findings of slightly reduced mean RBC glutathione synthesis in the present study and an elevated liver glutathione concentration in vitamin B-6–deficient rats in our previous report (11). Also, Hsu et al (44) found increased glutathione synthesis rates in vitamin B-6–depleted rat liver and only mildly increased RBC glutathione concentrations. In addition, it should be recognized that the effects of vitamin B-6 restriction on RBC glutathione synthesis would result from reduced PLP in the liver and other tissues capable of L-carbon metabolism and transsulfuration. The rat liver PLP concentration decreased proportionally to the dietary pyridoxine concentration, which indicated that the dietary vitamin B-6 supply affects the vitamin B-6 concentration and, therefore, the coenzyme function at the tissue level (11). Whereas the reductions in plasma and RBC PLP reflect the dietary vitamin B-6 intake, it should not be assumed that the fluxes of such PLP-dependent processes would be equally affected at various extents of vitamin B-6 deficiency.

In conclusion, we showed with this human tracer study, a rat model (11), and a mathematical model (45) that vitamin B-6 status has an effect on glutathione metabolism that varies from person to person. Our results also indicate that variations in the RBC glutathione synthesis rates and in glutathione concentrations do not occur as a result of an impaired supply of the precursor
REFERENCES


